OmniAb's reliance on licensing transgenic animals for drug discovery faces risks with FDA shifts and cash burn issues. Learn ...

Another effective way to assess whether an asset like gold has gotten ahead of itself is by looking at the Relative Strength ...

Last week’s news flow, market price action, and FOMC meeting set the stage for a continuation of the bull market. The tariff ...

Shell said two of its wells to boost production at the Perdido offshore development in the U.S. Gulf have been delayed to the ...

Semiconductor, Inc. is a unique growth stock with 20%+ revenue potential, undervaluation, and a rising EV market boost. Click ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Discover key insights from Harvard Bioscience's Q1 2025 earnings call: new product launches, market challenges, revenue outlook, and strategies for growth.

REITs, MLPs, and BDCs are some of the very best places to look for big and predictable dividends. I compare them side by side ...

Engie's strong results continue! Discover how renewable energy investments and strategic growth plans shape its future.

A lower-risk, diversified investment-grade floating rate note option with minimal drawdowns. Click for our FLTR update.

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Trump aims to cut US drug prices by 30-80% via Executive Order. Check out how pharma companies could be affected and how this ...